$3.50 -0.01 (-0.28%)
11/6/2009 4:00 PM

OraSure Technologies, Inc. (OSUR)

CAPS Rating: 4 out of 5

The Company develops, manufactures and markets oral specimen collection devices using its proprietary oral fluid technologies, diagnostic products including in vitro diagnostic tests, and other medical devices.

Current Price $3.50 Mkt Cap $160.57M
Open $3.46 P/E Ratio 70.50
Prev. Close $3.51 Div. (Yield) N/A (N/A)
Daily Range $3.43 - $3.51 Volume 103,188
52-Wk Range $2.16 - $4.15 Avg. Daily Vol. 202,000

OSUR News and Commentary

Caps

How do you think OSUR will perform vs the S&P 500?

Add Stock to Watchlist

All Members

162 Outperform
17 Underperform
 

All-Star Members

46 Outperform
8 Underperform
 

Wall Street

4 Outperform
2 Underperform
 

Top OSUR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

EDGAOSCHULTHEIS (< 20)
Submitted March 18, 2009

Management has underperformed in nearly every aspect in the past 4 years. Sales have fallen as products underperformed and continued delays in FDA approval of OTC oraquick product.

The fiest quarter of 2009 should prove the low point in… More

0 Comments | Reply | Report this Post

Drakeusx (81.46)
Submitted September 21, 2006

Too much of a large jump on nothing news.

0 Comments | Reply | Report this Post
OSUR VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about OSUR.

Recs

0
Member Avatar pennysplants (99.37) Submitted: 9/24/2009 11:53:32 AM : Outperform Start Price: $3.14 OSUR Score: +9.15

More than CMS, it's Premier's endorsement/contract that made me bullish on this long-term watchlist candidate.

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar EDGAOSCHULTHEIS (< 20) Submitted: 3/18/2009 11:37:43 AM : Outperform Start Price: $2.73 OSUR Score: -12.56

Management has underperformed in nearly every aspect in the past 4 years. Sales have fallen as products underperformed and continued delays in FDA approval of OTC oraquick product.

The fiest quarter of 2009 should prove the low point in company sales and earnings. Cryo produces are once again being dstributed (all be it in a limited form) after a year without distribution. FDA approval of HEP C should take place later this year and the light at the end of the (FDA OTC) approval for oraquick.

The market will discount these new revenue streams within the next few months (normally 6-9 months prior to FDA approval.

The company has nearly 1.62 / share net working capital and only trades about $1.00 above that level.

This is my first rating on CAPS so take everything with a grain of salt.

good luck

Do your own research

Report this Post 0 Comments | Reply | Permalink

Recs

1
Member Avatar sammeda (< 20) Submitted: 3/9/2009 8:02:09 PM : Outperform Start Price: $2.34 OSUR Score: -7.27

Hiv testing should be given priority

Report this Post 0 Comments | Reply | Permalink
View All 34 Pitches »

Leaderboard

Find the members with the highest scoring picks in OSUR.

Score Leader

TrackJimCramer

TrackJimCramer (< 20) Score: +54.96

The Score Leader is the member with the highest score across all their picks in OSUR.

Top
Pick 		Member Name Member
Rating 		Start
Date 		Call Time
Frame 		Start
Price 		Stock
Gain 		S&P
Gain 		Score Commentary
Drakeusx 81.46 9/21/2006 Underperform 3W $8.55 -59.06% -14.12% +44.95 1 Comment
bertyjamm < 20 8/22/2007 1/5/2009 Underperform 3Y $9.59 -63.50% -22.73% +40.77
markg993 < 20 10/10/2006 Underperform 3M $7.89 -55.64% -15.89% +39.75
illstocks 79.33 11/3/2008 12/9/2008 Underperform 3W $4.60 -23.91% +13.45% +37.37
derelict74 69.75 1/24/2007 Underperform 5Y $8.34 -58.03% -20.67% +37.36
yoyinski < 20 8/28/2006 Underperform 3M $6.54 -46.48% -11.92% +34.56
LocoriceFish 98.07 2/22/2008 Underperform NS $7.03 -50.21% -17.28% +32.94
luckofthedraw2 < 20 8/24/2009 Outperform 3W $2.56 +36.72% +4.11% +32.61
spiril 97.69 8/24/2009 Outperform NS $2.56 +36.72% +4.11% +32.61
KenN513 91.36 7/16/2007 Underperform 3Y $8.73 -59.91% -27.45% +32.46 1 Comment
View Complete Scorecard »

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating		 Start
Date		 Call Time
Frame		 Start
Price		 Stock
Gain		 S&P
Gain		 Score End Date Commentary
TrackSusquehanna 74.76 5/7/2008 Outperform NS $5.94 -41.08% -21.74% -19.34
TrackPacificGrow 90.86 12/19/2007 Outperform NS $8.58 -59.21% -23.09% -36.11
TrackNeedham < 20 10/15/2007 Outperform NS $10.30 -56.99% -13.81% -43.18 6/20/2008 @ $4.43
TrackLazardCapit < 20 5/4/2007 Outperform NS $7.57 -53.76% -24.87% -28.90
TrackDawsonJames 29.19 2/1/2007 Outperform NS $8.28 -57.73% -21.12% -36.61
TrackMatrix 89.45 9/11/2006 Underperform NS $6.66 -47.45% -12.05% +35.39
TrackJimCramer < 20 3/13/2006 Underperform 3W $10.22 -65.75% -10.79% +54.96

Featured Broker Partners